Kazia Therapeutics (KZIA) Total Non-Current Liabilities (2009 - 2025)
Kazia Therapeutics (KZIA) reported Total Non-Current Liabilities of $178697.5 for Q4 2025, down 94.75% on a YoY basis from $3.4 million in Q4 2024, and down 9.48% quarter-over-quarter from $197405.8 in Q2 2025.
Kazia Therapeutics (KZIA) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Kazia Therapeutics has reported Total Non-Current Liabilities for 15 years, with the latest figure at $178697.5 in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 94.75% year-over-year to $178697.5; the trailing twelve-month figure through Dec 2025 stood at $178697.5 (down 94.75% YoY), and the FY2025 full-year result was $197405.8, down 94.84% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $178697.5, down from $197405.8 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.2 million in Q2 2021, with the low at $178697.5 in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $5.1 million across 5 years, with a median of $5.4 million in 2023.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities surged 261.49% — and 2025, when it tumbled 94.84%.
- Kazia Therapeutics' Total Non-Current Liabilities stood at $8.4 million in 2021, then retreated by 16.92% to $7.0 million in 2022, then slipped by 27.76% to $5.1 million in 2023, then slumped by 32.76% to $3.4 million in 2024, then plunged by 94.75% to $178697.5 in 2025.
- The last three Total Non-Current Liabilities figures came in at $178697.5 (Q4 2025), $197405.8 (Q2 2025), and $3.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Kazia Therapeutics | 1.70 Bn | 1.70 Bn | - | 178,697.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 178,697.54 |
| Jun 30, 2025 | 197,405.85 |
| Dec 31, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.83 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Jun 30, 2023 | 5.66 Mn |
| Dec 31, 2022 | 7.01 Mn |
| Jun 30, 2022 | 7.80 Mn |
| Dec 31, 2021 | 8.44 Mn |
| Jun 30, 2021 | 9.17 Mn |
| Dec 31, 2020 | 3.81 Mn |
| Jun 30, 2020 | 2.54 Mn |
| Dec 31, 2019 | 3.52 Mn |
| Jun 30, 2019 | 3.56 Mn |
| Dec 31, 2018 | 3.45 Mn |
| Jun 30, 2018 | 3.82 Mn |
| Jun 30, 2017 | 3.90 Mn |
| Dec 31, 2016 | 3.74 Mn |
| Jun 30, 2016 | 3.87 Mn |
| Aug 30, 2013 | 1.55 Mn |